## ADUS: Addus HomeCare Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.0% below STRENGTH zone (3.0-6.0%); PEG 1.13 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($105.19)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Addus HomeCare (NASDAQ:ADUS) Director Esteban Lopez Sells 166 Shares**
- Source: MarketBeat | 20251208T230918 | Neutral | Relevance: 100%
-  Addus HomeCare (NASDAQ:ADUS) Director Esteban Lopez sold 166 shares of the company's stock on December 5th, totaling $18,721.48. This transaction reduced his stake by 4.13% to 3,850 shares. The stock traded down 1.9% to $111.09 and the company recently surpassed quarterly earnings estimates.

**2. Director Esteban Lopez Sells Shares of Addus HomeCare Corp**
- Source: GuruFocus | 20251208T180918 | Neutral | Relevance: 97%
- Director Esteban Lopez sold 166 shares of Addus HomeCare Corp (ADUS) on December 5, 2025, bringing his total ownership to 3,850 shares. Over the past year, Lopez has sold 688 shares with no purchases. Despite 36 insider sells and no buys for the company in the last year, ADUS is considered modestly undervalued with a price-to-GF-Value ratio of 0.9.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | BMO Capital | $120 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | BMO Capital | init | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Blackrock Inc.: 14.8% (-1.1%)
- Vanguard Group Inc: 7.0% (+2.9%)
- Capital Research Glo: 6.5% (+9.0%)
- Wasatch Advisors LP: 5.1% (+0.8%)
- Silvercrest Asset Ma: 4.6% (+14.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.13 suggests fair value with growth premium. Balance sheet: low leverage (D/E 0.36). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.1B |
| Beta | 0.94 |
| 52W Range | $88.96 - $136.72 |
| Short Interest | 4.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.13 |
| Forward P/E | 16.4 |
| Current P/E | 18.2 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.2% to -5.0% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.0pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.95% (CS: 8) | Weak |
| RSI_14 | 43.9 | Neutral |
| MACD Histogram | -0.39 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.969x | Below |
| vs SMA200 | 1.024x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $112.19
- **Stop Loss:** $105.19 (6.2% risk)
- **Target:** $119.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 42
- **Position Value:** $4,711.98
- **Portfolio %:** 4.71%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-23 (Est: $1.72)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.53 | $1.56 | +1.7% |
| 2025Q2 | $1.46 | $1.49 | +1.8% |
| 2025Q1 | $1.33 | $1.42 | +6.5% |
| 2024Q4 | $1.36 | $1.38 | +1.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*